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Abstract 
Background: The rapid growth of Qatar in the last two decades has attracted a large influx of immigrant workers 
who mostly come from HEV‑hyperendemic countries. Thus, we aim to investigate the prevalence of HEV among acute 
non‑A‑C hepatitis patients in Qatar; and to evaluate the performance of four dominant commercial serological assays 
for HEV diagnosis.
Methods: 259 patients with non‑A‑C hepatitis were tested using the Wantai HEV‑IgM, HEV‑IgG, HEV‑Ag ELISA kits, 
and the MP Biomedical HEV‑Total Ab ELISA kit. ALT levels were tested and HEV RNA (viral loads) was performed using 
Taqman AmpliCube HEV RT‑PCR kit (Mikrogen, Neuried, Germany). The performance of each kit was assessed accord‑
ing to the RT‑PCR results.
Results: HEV‑RNA was detected in 23.1% of the samples. Most of these HEV‑RNA‑positive cases belonged to non‑
Qatari residents from the Indian subcontinent; India, Pakistan, etc. HEV‑Ag, HEV‑IgM, HEV‑IgG, HEV‑Total Ab were 
detected in 5.56%, 8.65%, 32.1%, and 34.2% of all tested samples, respectively. Elevated ALT levels were highly cor‑
related with the HEV‑Ag, HEV‑IgM, HEV‑RNA but not with the HEV‑IgG and HEV‑Total Ab. Although HEV‑Ag was very 
specific (100%), yet its sensitivity was poor (36.7%). HEV‑IgM demonstrated the best second marker for diagnosis of 
acute HEV after RT‑PCR as jugged by the overall performance parameters: specificity (96.2%), sensitivity (71.4%), PPV 
(83.3%), NPP (92.7%), agreement with RT‑PCR (91.0%), and Kappa‑value (0.71).
Conclusion: Our study demonstrated a high prevalence of HEV virus in Qatar, mostly among immigrants from the 
Indian subcontinent. The HEV‑IgM represents the best marker for detecting the acute HEV infection, where RT‑PCR 
cannot be performed.
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Background
HEV was first identified in Afghanistan in 1983 [1]. It is a 
single-stranded RNA, non-enveloped, and the only mem-
ber of the genus Herpesvirus in the Hepeviridae family 
[2]. Hepatitis E is one of the leading causes of acute liver 
inflammation globally [3, 4]. According to the World 
Health Organization (WHO), there are an estimated 20 
million HEV infections worldwide every year, leading to 
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an estimated 3.3 million symptomatic cases of hepatitis 
E globally [5]. In addition, WHO estimates that hepatitis 
E caused approximately 44,000 deaths in 2015 (account-
ing for 3.3% of the mortality rate due to viral hepatitis) 
[5]. Furthermore, HEV constitutes a major concern for 
public health, especially in developing countries [6–8]. 
Even though Hepatitis E is a self-limiting disease, it may 
develop into acute fulminant hepatitis (acute liver failure) 
[5]. Unlike other forms of viral hepatitis, HEV infection 
in pregnant women induces a high rate of mortality rang-
ing from 15 to 20% [3, 7, 9]. This virus is predominantly 
transmitted through the fecal–oral route. However, other 
routes have been recently identified, including vertical 
transmission and blood transfusion [10, 11].
HEV is a major public health problem in the Middle 
East, where its prevalence ranged from 2.0 to 37.5% and 
higher in males than in females [8]. Studies in Saudi Ara-
bia showed a prevalence of HEV surface antigen ranging 
from 7.4 to 17%, denoting high endemicity [12, 13]. In 
addition, a study performed in Dubai-UAE in 2006 and 
2007 revealed that 40% of the acute hepatitis cases had 
HEV infection [14]. Moreover, in the Dakhliya region in 
Oman, screening of all cases of acute hepatitis in 2003 
and 2004 revealed that 12 of 73 (16.4%) confirmed viral 
hepatitis cases were positive for HEV [15]. However, 
data on the seroprevalence of HEV antibodies in Qatar 
is scarce due to the lack of enough epidemiological data.
With the anticipation of the FIFA World Cup 2022, 
Qatar has seen a spurt of foreign labor with expatriates 
constituting 95% of a total labor force from over 90 coun-
tries [16–21]. The majority of these workers usually come 
from highly HEV-endemic regions like India, Nepal, 
Bangladesh, Philippine, Pakistan Sudan, and Egypt. We 
had shown that the prevalence of anti-HEV IgG and IgM 
among blood donors of some of these nationalities is 
more three folds of the local people [22]. Besides, poor 
sanitation and hygiene as well as sharing accommodation 
among this group of population increase the risk of trans-
mitting acute hepatitis infection. Recently, more evidence 
has been accumulating for the direct person-to-person 
transmission of HEV and nearly 80% of cases could be 
from households with more than one case [23, 24]. This 
suggests that this group of immigrants increase the 
chances of spreading communicable diseases in the com-
munity, such as HEV. Thus, we strongly believe that most 
of the HEV cases in Qatar were also imported from out-
side through a high influx of migrant workers to Qatar or 
by traveling back and forth to these highly HEV-endemic 
areas. Therefore, in this study, we aimed to investigate the 
prevalence of HEV among non-A-C hepatitis in Qatar.
HEV-RNA detection by RT-PCR remains the gold 
standard to uncover the true HEV viremia and acute 
infection, particularly in asymptomatic cases [25, 26]. 
However, there is a pressing need for identifying reliable 
immunoassays with high sensitivity and specificity for 
serology testing and surveillance of HEV infection to be 
used as a complementary test to RT-PCR to improve its 
diagnostic sensitivity. Recently, an enzyme immune-assay 
(ELISA) for HEV-Ag detection was released into the mar-
ket. The sensitivity results for this assay was very con-
troversial. Some reported low [11] and others reported 
high [27, 28] concordance with the HEV-RNA detection 
RT-PCR assay. The clinical impact of hepatitis E in Qatar 
remains to be clarified, as the increased sensitivity and 
specificity of the last generation assays suggest a reassess-
ment of previous percentages. Therefore, in the present 
study, we evaluated the performance of four dominant, 
commercially available serological assay kits for detect-
ing anti-HEV-IgG, HEV-IgM, HEV-Ag, HEV-Total Ab in 
samples from 259 non-A-C hepatitis patients (Additional 
file 1: Table S1). We also compared the sensitivity, speci-
ficity, predictive values, and Cohen’s Kappa of these kits 
in relation to RT-PCR. A strength of this study is that it 
was conducted on a very diverse population reflecting 
the diversity of the population of Qatar.
Methods
Ethical approval
This study was conducted in full accordance with the 
regulation of research at Hamad Medical Corporation 
(HMC) and Qatar University (QU). HMC-Institutional 
Review Board (HMC-IRB #14292/14) and QU-IRB 
(#556-EA/16) were obtained before sample collection.
Sample collection and description
From March 2017 to September 2019, 259 anonymous 
leftover serum samples were collected from the clinical 
virology lab at HMC. These samples belonged to clini-
cally suspected hepatitis patients. They were classified 
by the clinical virology lab as suspected non-A-C viral 
hepatitis patients, because of the negative serology for 
anti-HAV-IgM, anti-HBc IgM, and HCV-RNA. Hepatitis 
caused by other diseases, such as autoimmune and drug-
induced hepatitis, were not excluded from the study. 
Patients were not contacted or recruited. Only basic 
demographic data such as age, gender, and nationality 
were only collected from these patients.
Detection of HEV‑RNA using Real‑Time PCR
RNA was extracted from 200 μL aliquots of serum using a 
standard qualitative commercial kit for viral RNA extrac-
tion from body fluids (QIAamp® Viral RNA Mini Kit 
Qiagen; Hilden, Germany) according to the manufactur-
er’s instructions. Reverse transcription and amplification 
of HEV RNA were performed from 10 μL of the extracted 
RNA according to the manufacturer’s instructions of 
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the AmpliCube HEV RT-PCR kit (Mikrogen, Neuried, 
Germany) using QuantStudio™ 6 Flex Real-Time PCR 
instrument (Applied Biosystems, USA). The cycle thresh-
old (CT) was calculated according to the manufacture’s 
instruction. Samples with CT value more than 40 were 
considered negative.
Detection of HEV‑Ag, HEV‑IgG, HEV‑IgM, and HEV‑Total Ab 
by ELISA
All serum samples were screened for the presence of 
the HEV-Ag using the Wantai HEV-Ag ELISA kit (Cat. 
no. WE-7596, Wantai Biological Pharmacy Enterprise 
Co., Ltd., Beijing, China), HEV-IgM using Wantai HEV-
IgM kit (Cat. no. WE-7196, Wantai Biological Pharmacy 
Enterprise Co., Ltd., Beijing, China) and HEV-IgG using 
Wantai HEV-IgG kit (Cat. no. WE-7296, Wantai Bio-
logical Pharmacy Enterprise Co., Ltd., Beijing, China) 
according to the manufactures’ instructions. Besides, MP 
Diagnostics ELISA kit was used to detect HEV total anti-
bodies, which are HEV-IgG, HEV-IgA, and HEV-IgM. 
The cut-off value of the tests were defined by the positive 
and the negative control sera that were included in each 
kit.
Measuring alanine aminotransferase (ALT)
ALT level is one of many factors that give insight as to 
whether HEV infections are acute or chronic. The ALT 
was measured using Greiner Diagnostic ALAT / GP 
(GmbH - Unter Gereuth 10 – D-79353 Bahlingen – 
Germany). A total of 20 µLof each sample were used as 
per manufacturer’s instructions. Samples were incu-
bated with 200 µL of stock solution previously prepared 
from reagent 1 and reagent 2 for three minutes. Regent 
1 contained Tris-buffer (pH 7.5), l-alanine and lactate 
dehydrogenase (LDH), while reagent 2 contained 2-oxo-
gutarate and NADH. The absorbance was read at 334 nm 
after each minute of incubation. Subsequently, the delta 
of the three absorbance results was obtained, and the 
final results were obtained as follows: 1 = R3 − R2 ; 





= (�1+�2 ) ∗ 1780 . 
Results were interpreted according to the reference val-
ues provided by the manufacturer. Female subjects with 
ALT levels < 31 U/L were considered normal while male 
subjects with ALT values < 41  U/L were considered 
normal.
Statistical analysis
The diagnostic assessment of the four assays with RT-
PCR for HEV resulted in four cross-tabulations. Using 
RT-PCR as the reference standard, overall percent agree-
ment, sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and Cohen’s 
kappa statistic were calculated to assess the performance 
of each assay. The overall agreement between two assays 
usually measured by the overall percent agreement and 
Cohen’s kappa. The overall percent agreement is the 
percentage of total subjects where the new test and the 
non-reference standard agree. Whereas, Cohen’s kappa 
statistic is a standard and robust metric that estimates 
the level of agreement (beyond chance) between two 
diagnostic tests. Ranging between 0 and 1, a kappa value 
below 0 denotes no agreement, a kappa value between 
0.00 and 0.20 denotes slight agreement, a kappa value 
0.21 and 0.40 fair agreement, a kappa value between 0.41 
and 0.60 denotes moderate agreement, a kappa value 
between 0.61 and 0.80 denotes substantial agreement, 
and a value between 0.81 and 1.00 denotes an almost 
perfect agreement [29]. We considered all borderline 
samples to be positive as informed by literature [30, 31]. 
The significance level was indicated at 5%, and a 95% con-
fidence interval (CI) was reported for each metric. All 
calculations were performed using Microsoft Excel 2016 
and GraphPad Prism 8 software (version 8.2.1).
Results
Patients characteristics
A total of 259 serum samples of patients with suspected 
non-A-C hepatitis were anonymously collected from the 
clinical virology lab at HMC. The mean age in our studies 
patients was 39.4 ± 14.92 with the youngest age being 6 
and the oldest being 98 years old. Approximately 50% of 
the patients were aged 25–44 years. 61.4% of the samples 
belonged to males, while the rest were from females. The 
relative distribution of samples by nationality showed 
that Indians (20.8%) comprised the largest percentage, 
followed by Qataris (20.5%), Nepalese (9.65%) and Egyp-
tians (9.27%) and the rest were from other nationalities. 
Table 1 highlights the main demographic characteristics 
of non-A-C patients’ samples.
HEV‑RNA, HEV‑Ag, HEV‑IgG, HEV‑IgM, and HEV‑Total Ab, 
and ALT results
RT-PCR testing is considered the gold standard test for 
the diagnosis of acute HEV in immunocompromised 
patients [32, 33]. Whereas, serology in combination with 
RT-PCR are recommended for HEV diagnosis in immu-
nocompetent patients [32]. The HEV-RNA was identified 
by RT-PCR in 23.1% of the samples. The HEV-Ag, HEV-
IgG, and HEV-IgM markers were identified by Wantai 
ELISA kits in 5.56%, 32.1%, and 8.65% of the samples, 
respectively. While HEV-Total Ab were identified by MP 
Diagnostics ELISA in 34.2% samples.
ALT values were available for 235 out of 259 specimens. 
Interestingly, the median ALT values for the HEV-RNA 
positive specimens was 379 IU/L (95–1314 IU/L), which 
is almost three-fold greater than negative HEV-RNA 
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specimens (86.5 IU/L (23.5–277 IU/L)). Only one of the 
positive RNA specimens (No. 68, Table  2) showed nor-
mal ALT values. As shown in Table 3, elevated ALT lev-
els were highly correlated with the HEV-RNA, HEV-Ag, 
HEV-IgM but not with the HEV-IgG and HEV-Total Ab. 
Yet, 64 (27.2%) of the samples had elevated ALT with 
negative HEV RNA and IgM results.
HEV‑RNA and serological markers association with age, 
gender, and race
In regard to age, as expected, HEV-IgG seropositivity 
increased significantly with age (Table  1); seropreva-
lence peaked among 55+ year-olds (50%), compared 
with 28.9% among those < 24  years of age (p < 0.024). 
A similar trend was observed with HEV-Total Ab; 
Table 2 RT‑PCR confirmed HEV Patients’ demographic data, ALT, RT‑PCR and serology results
ALT reference range: 0 U/L–41 U/L
*ND Not done because of no sufficient sample
**(+++) or highly positive: CT value < 20; (++) or moderately positive: CT value from 20 to 30; (+) weakly positive: CT value between 30 and 40; (−) or negative CT 
value less than 45 considered negative







34 2766 Indian + + + + +
43 1314 Indian + + + (++) 23 +
44 2346 Indian + + + (+) 32 +
45 3569 Indian − + + (++) 22 +
46 40 Indian + + + (++) 29 −
49 ND Egyptian + − + (+++)10 −
50 919 Bangladeshi + + + (+) 31 −
52 ND Pakistanis + + + (+)36 +
53 ND Bangladeshi + + + (+) 30 +
54 1321 Bangladeshi + + + (+) 31 −
55 107 Qatari − − − (+++)19 −
63 146 Egyptian − − + (+) 39 −
66 42 Nepalese − − − (+) 31 −
67 379 Indian − − − (+) 36 −
68 15 Qatari − − − (+) 39 −
72 947 Indian + ND* + (+) 30 +
74 396 Indian + + + (+) 32 −
75 1122 Indian + + + (+) 34 +
85 ND Indian ND ND ND (++) 28 ND
86 91 Pakistanis ND ND ND (+) 38 ND
87 99 Pakistanis − + + (++) 20 −
88 103 Sudanese + + + (+) 30 −
89 ND Nepalese + + + (+) 30 −
90 95 Siri Lankan − + − (+) 32 −
Table 3 Summary of the positive results obtained by each assay to detect the presence of HEV among non‑A‑C hepatitis patients in 
Qatar (n = 259)
ALT test was not done in all samples due to insufficient volume
HEV marker No. positive (%) Total no. of ALT tested 
specimen
Sample no. with normal 
ALT (%)
Sample no. with an 
elevated ALT (%)
Wantai‑IgM 20 (8.65) 17 2/17 (11.8) 15/17 (88.2)
Wantai HEV‑IgG 74 (32.1) 69 17/69 (24.6) 51/69 (73.9)
Wantai HEV‑Ag 10 (5.56) 8 0 (0) 8/8 (100)
MP HEV‑Total Ab 53 (34.2) 49 13 (26.5) 36/49 (37.5)
RT‑PCR HEV‑RNA 24 (23.1) 19 1 (5.3) 18/19 (94.7)
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the highest rate of HEV-Total Ab seroprevalence was 
observed in the eldest group (55+, 62.5%). Incon-
trast, HEV-IgM serevoprevelence peaked (21.1%) in 
the youngest age group (< 24  years of age). Overall, 
HEV-IgG, HEV-IgM, HEV-Ag, and HEV-Total Ab 
seropositivity were significantly associated with age in 
non-A-C hepatitis patients in Qatar (p < 0.05) as shown 
in Table 1.
With regard to gender and race, HEV-IgG sero-
positivity was significantly associated with gender 
(p = 0.01); 38.3% of males and 22.4% of females were 
positive for HEV-IgG antibodies. In addition, HEV-IgG 
seropositivity was statistically associated (p = 0.03) 
with race, where 38.8% and 39.4% of the patients were 
coming from the Indian subcontinent group and North 
African, respectively. Similarly, the seroprevalence of 
HEV-IgM and HEV-Total Ab were significantly higher 
among males (p = 0.0001 and p = 0.025, respectively) 
compared to females. In addition, a significant associa-
tion was observed between the seropositivity of HEV-
IgM with race, where the highest seroprevalence was 
observed in patients coming from the Indian subconti-
nent area. Further, a significant association was found 
between samples testing positive for HEV-RNA and 
having been born in the Indian subcontinent region 
(36.5%, p = 0.03) (Fig. 1, Table1).
Sensitivity, specificity, and concordance of HEV serological 
assays compared to RT‑PCR
We assessed the performance of HEV-Ag, HEV-IgG, 
HEV-IgM, and HEV-Total Ab test to be used as a com-
plementary test to RT-PCR to improve its diagnostic 
sensitivity in clinical settings. The sensitivity, specificity, 
predictive values, and concordance of these assays were 
evaluated in comparison with the RT-PCR reference 
assay. MP HEV-Total Ab assay showed the highest sen-
sitivity of 77.3%, followed by Wantai HEV-IgM (71.4%), 
Wantai HEV-IgG (63.6%), and Wantai HEV-Ag (36.3%). 
Although Wantai HEV-Ag showed the lowest sensitiv-
ity (36.3%), yet, it had the highest specificity (100%). 
The overall percent agreement was 91.0% for Wantai 
HEV-IgM, followed by 81.1% for Wantai HEV-Ag, 73.2% 
for MP HEV-Total Ab, and 70.3% for Wantai HEV-
IgG. Importantly, the agreement with RT-PCR results 
based on Cohen’s kappa was as follows: Wantai IgM 
ELISA (0.71) > MP HEV-Total Ab and Wantai HEV-Ag 
(0.44) > Wantai HEV-IgG (0.29). Therefore, based on the 
overall Cohen kappa and overall agreement with RT-
PCR, MP HEV-Total and Wantai HEV-IgG showed the 
poorest performance and agreement with RT-PCR.
Discussion
Acute HEV infection can be diagnosed by the detection 
of anti-HEV antibodies (IgM, IgG or both) by enzyme 
immunoassays. However, till now, there are plethora 
Fig. 1 Representative figure of the seroprevalence (with 95% confidence intervals) of HEV‑IgG, HEV‑IgM, HEV‑Ag, HEV‑Total Ab and RT‑PCR in 
non‑A‑C hepatitis patients in Qatar. Indian Subcontinent includes Bangladesh, India, Nepal, Pakistan, and Sri Lanka. Western Asia includes Syria, 
Lebanon, Jordan, Palestine, Oman, Iran, Bahrain, Saudi Arabia, Yemen, and Qatar. Southeast Asia includes Philippines, and Myanmar. North Africa 
includes Sudan, Algeria, Tunisia, Sudan, and Egypt. Other includes Eretria, Spain, America, Europe, Uganda, Somalia, Cuba, and Mexico N = 259. 
*p < 0.05
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of issues regarding the performance of HEV serological 
assays that require urgent attention, such as, the specific-
ity of certain assays is not optimal, cross reactivity with 
other viruses (EBV and CMV), and anti-HEV IgM on 
its own is not a sufficiently robust marker for diagnosis 
[34]. Therefore, serology assays alone are unreliable in 
the diagnosis of acute viral hepatitis. Thus, the European 
Association of the Study of the Liver (EASL) recom-
mends using a combination of serology and nucleic acid 
test (NAT) testing to diagnose HEV infection in immu-
nocompetent patients, while it recommends NAT testing 
to diagnose chronic HEV infection in immunocompro-
mised patients [35]. In the present paper, we conducted 
a study on sporadic cases of acute non-A-C hepatitis 
in Qatar by comparing the performance of four domi-
nant, commercially available Wantai HEV-IgM, Wantai 
HEV-IgG, Wantai HEV-Ag assays, and MP HEV-Total 
Ab test to RT-PCR to evaluate the current status of their 
performance.
Acute HEV infections were identified in 23.1% of the 
non-A-C hepatitis patients in our study. However, this 
prevalence of HEV-RNA could be underestimated. That 
is, the HEV-RNA can be detected in serum only during 
the viremia stage and last for a very short period dur-
ing the early convalescence stage [3, 9, 26]. For instance, 
three samples in our study showed positive HEV-IgM, 
HEV-IgG, HEV-Total Ab and high ALT value, but nega-
tive RT-PCR results. These 3 patients could be in an early 
convalescence stage, where RNA disappeared or could be 
due to the low level of HEV-RNA in their serum [36]. As 
the HEV-RNA detected for a longer period in the stool 
than the blood during the acute stage [37], any future 
study should include stool samples from these patients 
for better estimation of the HEV prevalence.
In the 24 RNA positive specimens that were tested 
by all assays, HEV antibodies were identified in 66.7% 
(16/24) of the patients, at least, by two serological assays, 
as shown in Table 2. Thus, in agreement with the dynamic 
of acute infection, 66.6% of patients were in the early 
post-seroconversion stage (all three markers positive) 
[38]. Only three patients (No. 55, 66, and 67) were in the 
window period of the acute phase where antibodies were 
not yet detectable, and viremia and increased ALT values 
were the only markers of infection. Another reason could 
be that these patients might not have elicited enough 
antibody response as the samples were collected too early 
to be positive during the acute phase. These results sug-
gest that ALT could also be used as a good acute HEV 
marker as well. On the other hand, one sample (No. 68) 
showed positive RT-PCR test, negative serology testing 
and normal ALT level (15 IU/L). This sample most likely 
belongs to an asymptomatic patient.
Zhang et  al. has indicated that HEV-Ag in macaques 
became detectable in the serum at almost the same time 
as HEV-RNA in feces [28]. They and others suggested 
that HEV-Ag detection should be a valuable tool for 
the diagnosis of acute HEV, particularly in the window 
period before seroconversion to anti-HEV [28, 33]. To 
our knowledge, Wantai Ag-ELISA is the only commer-
cial assay that is currently present in the market for the 
diagnosis of HEV Ag. Our study is one of the very few 
studies that evaluated the performance of HEV Ag for the 
diagnosis of acute HEV [11, 39, 40]. However, our results 
showed that the sensitivity Wantai Ag-ELISA was the 
lowest (36.4%) compared to the other serological assays, 
as shown in Table 4, suggesting that the Wantai HEV-Ag 
might not be very useful to be used as a single screening 
assay. In addition, the Wantai HEV-IgM and MP HEV-
Total Ab conventional assays showed better sensitivity 
of 71.4% and 77.3%, respectively, suggesting that Wantai 
HEV-IgM and MP HEV-Total Ab assays for diagnosis of 
acute HEV are superior to HEV-Ag assay. Our study con-
firms the findings of a recent study conducted by Vollmer 
et  al., where they evaluated the performance of Wantai 
HEV-Ag and HEV-IgM assays for the detection of HEV-
Ag and HEV-IgM in positive blood donors in comparison 
to the RT-PCR assay [11, 40]. In Vollmer’s study, Wantai 
HEV-Ag was able to detect HEV-Ag only in 40% (4/10) 
of the positive HEV-RNA donors. In addition, HEV-IgM 
was detected in 70% (7/10) of the same donors, which 
Table 4 Assays performance according to the RT‑PCR assay
The overall percent agreement is the percentage of total subjects where the new test and the non-reference standard agree




Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) Cohen’s Kappa value 
(CI)
Wantai HEV‑Ag 81.1 (70.7–88.4) 36.7 (16.3–56.5) 100.0 (100–100) 100.00 (100–100) 78.7 (68.9–88.7) 0.44 (0.22–0.66)
Wantai HEV‑IgM 91.0 (83.8–95.2) 71.4 (52.1–90.8) 96.20 (91.9–100) 83.3 (66.1–100.5) 92.6 (87.0–98.3) 0.71 (0.53–0.88)
Wantai HEV‑IgG 70.3 (60.8–78.3) 63.64(43.5–83.7) 72.15 (62.3–82.0) 38.8 (22.9–54.8) 87.6 (79.7–95.6) 0.29 (0.10–0.48)
MP HEV‑Total Ab 73.2 (61.9–82.1) 77.27 (59.8–94.8) 71.43 (58.8–84.1) 54.8 (37.3–72.3) 87.5 (77.2–97.7) 0.44 (0.23–0.64)
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are in agreement with our results. In contrast, two other 
studies had demonstrated that Wantai HEV-Ag assay 
could be used as an alternative early detection marker for 
the diagnosis of acute HEV [39–41] and HEV-Ag dem-
onstrated a good concordance with HEV-RNA, while the 
presence of HEV-IgM did not demonstrate any concord-
ance with HEV-RNA [39]. However, our findings, along 
with Vollmer et al. results, showed a significant diagnos-
tic gap between the presence of HEV-RNA and HEV-Ag 
(kappa 0.44) by ELISA and to a lesser degree, with HEV-
IgM by ELISA tests (kappa 0.71).
The seroprevalence of MP HEV-Total Ab (IgG, IgM 
and IgA) was the highest among non-A-C hepatitis 
patients (34.2%) followed by Wantai HEV-IgG (32.1%) 
and Wantai HEV-IgM (8.65%) as shown in Table 1. Our 
results are almost similar to the recent study [22], where 
they reported high seroprevalence for HEV-IgG (18.0%) 
among blood donors in Qatar. However, as expected, 
HEV-IgM was much higher in acute non-A-C hepatitis 
patients (8.65%) compared to blood donors (only 0.20%) 
[22]. In this study, we included participants from 32 dif-
ferent countries. Most of the migrants resides in Qatar 
for a minimum of 2 years. We showed here that highest 
HEV-IgG antibody seroprevalence belonged to partici-
pants from Bangladesh, Egypt, Nepal, India, Pakistani, 
Sudan, Philippine, and SriLanka with seroprevalences of 
50, 47.6, 47.5%, 37.5, 36.4, 30.0, 30.0, and 20%, respec-
tively. Meanwhile, Qatar comes at a much lower sero-
prevalence of 17% as shown in Additional file 1: Table S2. 
These results were consistent with our previous study, 
in which, we included 5854 blood donor participants 
from more than 100 different countries. The highest 
HEV antibody seroprevalence belonged to blood donor 
participants from Sudan, Pakistan, Egypt, Yemen, Syria, 
and India with seroprevalences of 51.5, 40.9, 38.8%, 18.8, 
15.8, and 15.1 respectively. Similar to our findings, Qatar 
comes at a much lower seroprevalence of 11.5%, even 
though Qataris were the largest community of blood 
donation [42]. The prevalence of HEV antibody–positive 
cases among non-Qataris is nearly double that of Qataris 
(22.9% vs. 11.5%, respectively), with a significant statisti-
cal association (p < 0.001)[42].
Even though the Wantai HEV-IgG resulted in a sig-
nificantly higher seroprevalence (Table  3), it showed 
the weakest performance compared to the rest of the 
assays (sensitivity = 63.6%, specificity = 72.1%, and 
kappa = 0.29). The reason behind this might be because 
all the samples were collected in the acute phase of the 
infection, where HEV-IgG immunoglobulins are yet 
below the detectable limits. In other words, HEV IgG 
appears shortly after the IgM response, which appears 
one week to two months after the onset of illness. Similar 
to our results, in a series of 44 children with acute HEV 
(confirmed with HEV viremia in serum and stool by cell 
culture and RT-PCR), only 35 percent of patients tested 
positive for HEV-IgM in serum and only 3 percent were 
positive for HEV-IgG [43]. In another study, HEV-RNA 
was detected in 23% of patients, followed by the detec-
tion of specific HEV-IgM in 17% and HEV-IgG in 13% 
of patients. This might explain the high discordance 
between assays of HEV-IgG antibody (depending on the 
time of sample collection) as compared with assays for 
HEV-IgM antibody [44]. Another reason, IgG positivity 
could be due to a previous infection, especially those that 
are HEV-RNA and HEV-IgM negative samples.
HEV usually causes acute hepatitis; however, it also 
can develop chronic infection [4]. HEV has 4 main well 
established and 3 recently discovered genotypes, which 
all have dictint epidemiological distinct pattern based 
on socioeconomic factors and ecology [45, 46]. All HEV 
genotypes can cause human infections. HEV‐1 and 
HEV-2 solely infect humans and lack any zoonotic origin. 
HEV-1 accounts for epidemics in parts of Asia [9], while 
HEV‐2 is more prevalent in Africa, Mexico, and other 
developing countries. In countries with poor resources 
and low sanitation such as India, Bangladesh, Sri Lanka, 
Egypt, Mexico, and China, HEV‐1 and HEV‐2 infections 
manifest as large‐scale water-borne epidemics (fecal–oral 
transmission) and have spread through person‐to‐ person 
contact [4, 47]. On the other hand, HEV-3 and HEV-4 
have zoonotic origins and primarily infect pigs, boars 
and deer. HEV‐3 and HEV‐4 are transmitted zoonotically 
in developed countries such as Japan, USA, and several 
European countries with sporadic cases [4, 47]. HEV‐3 
is prevalent worldwide, while HEV‐4 is mainly prevalent 
in Asia. Both HEV‐3 and HEV‐4 are transmitted through 
contact with infected animals and by consumption of 
contaminated raw or undercooked beef, pork, or shellfish 
[4, 47]. Finally, HEV‐5 and HEV‐6 are novel genotypes 
identified in wild boar in Japan [48, 49], while, HEV‐7, 
a newly discovered HEV genotype, primarily infects 
dromedary camels (Arabian 1‐humped camels) and was 
identified in the UAE very recently [45]. To this end, as 
most of HEV-RNA-positive cases in our study belong to 
non-Qatari residents, particularly, from the Indian sub-
continent (India, Pakistan and Bangladesh), we expect 
that most prevalent genotype would be HEV-1, followed 
by HEV-3. As shown Table  2, 19 samples out of the 24 
HEV positive samples (79%) were from immigrant work-
ers coming from South Asia (Bangladesh, India, Nepal, 
Pakistan and Sri Lanka). Recently a new genotype 7 was 
isolated in UAE (close to Qatar) from both camels and 
humans, yet it is now known if this genotype would also 
be found in Qatar [50, 51]. Indeed, several studies from 
Europe and Italy, targeted HEV prevalence in migrant 
population, have shown that HEV-1 is the most imported 
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and prevalent genotype among Asian migrants such 
Indian, Pakistani Bengali and Nepali migrants[52–55].
Overall, our data suggest that HEV-IgM positivity rep-
resents the main biological marker of HEV acute infec-
tion in the clinical setting of developed countries as it 
showed the best overall performance and best concord-
ance with RT-PCR with a kappa value of 0.71, which 
denotes substantial agreement. Although Wantai HEV-
Ag is the only commercial assay that is currently pre-
sent in the market for the diagnosis of acute HEV-Ag, 
the employment of this assay with such a low sensitiv-
ity (36.36%) could erroneously fail to confirm HEV-IgM 
results and could cause drastic underestimation of acute 
HEV infection cases [56].
Conclusion
HEV leads to outbreaks in developing countries and 
causes significant morbidity and mortality in immuno-
compromised and pregnant females. Our knowledge of 
HEV infection has increased dramatically over the past 
20 years. HEV laboratory findings and clinical symptoms 
related to HEV infection are vague and common among 
other hepatitis infections. In addition, the use of HEV-
antibodies diagnostic tests of low specificity and sensitiv-
ity has made HEV diagnosis difficult and challenging. We 
recommend performing routine RT-PCR HEV in all cases 
of acute non-A-C hepatitis. However, a combination of 
serology and RT-PCR is the recommended testing strat-
egy for suspected patients, when applicable. Thus early 
detection accurate diagnosis of HEV infection. Although 
we observed significant inconsistencies between differ-
ent serological assay kits and HEV RNA assay, caution 
is warranted while interpreting the results of both sero-
logical and RT-PCR in HEV diagnoses. We believe that 
the knowledge of the analytical sensitivity towards all the 
HEV genotypes gains fundamental importance to assess 
the reliability of the test in HEV acute infection diagno-
sis, especially during an outbreak and other emergencies 
in countries with limited resources.
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